Los Angeles Capital Management LLC Spectrum Pharmaceuticals Inc Transaction History

Los Angeles Capital Management LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$1.27 - $2.42 $235,237 - $448,246	-185,226 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$2.15 - $3.82 $33,067 - $58,751	-15,380 Reduced 7.67%	185,226 $404,000
Q2 2021 Aug 05, 2021	SELL	$2.89 - $4.45 $447,291 - $688,735	-154,772 Reduced 43.55%	200,606 $752,000
Q1 2021 May 05, 2021	BUY	$2.9 - $4.09 $838,627 - $1.18 Million	289,182 Added 436.86%	355,378 $1.16 Million
Q4 2020 Feb 04, 2021	BUY	$3.38 - $5.14 $27,134 - $41,263	8,028 Added 13.8%	66,196 $226,000
Q3 2020 Nov 02, 2020	SELL	$2.99 - $4.9 $108,991 - $178,614	-36,452 Reduced 38.52%	58,168 $237,000
Q2 2020 Aug 05, 2020	BUY	$2.11 - $3.38 $78,597 - $125,905	37,250 Added 64.93%	94,620 $319,000
Q1 2020 May 04, 2020	BUY	$1.83 - $3.45 $77,171 - $145,486	42,170 Added 277.43%	57,370 $134,000
Q4 2019 Feb 07, 2020	BUY	$3.5 - $10.35 $53,200 - $157,320	15,200 New	15,200 $55,000
Q3 2019 Nov 07, 2019	SELL	$7.03 - $9.7 $257,227 - $354,923	-36,590 Closed	0 $0
Q2 2019 Jul 29, 2019	BUY	$7.36 - $11.26 $113,638 - $173,854	15,440 Added 73.0%	36,590 $315,000
Q1 2019 Apr 25, 2019	BUY	$9.08 - $11.84 $192,042 - $250,416	21,150 New	21,150 $226,000
Q3 2018 Nov 05, 2018	SELL	$16.52 - $24.82 $195,547 - $293,794	-11,837 Closed	0 $0
Q2 2018 Jul 31, 2018	BUY	$14.31 - $21.75 $169,387 - $257,454	11,837 New	11,837 $248,000
Q4 2017 Feb 05, 2018	SELL	$13.36 - $20.73 $167,801 - $260,368	-12,560 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$8.75 - $14.07 $109,900 - $176,719	12,560	12,560 $177,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.